West Pharmaceutical Services (NYSE:WST) Surprises With Strong Q1 CY2026, Stock SoarsHealthcare products company West Pharmaceutical Services (
NYSE:WST) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 21% year on year to $...
Earnings To Watch: West Pharmaceutical Services (WST) Reports Q1 Results TomorrowHealthcare products company West Pharmaceutical Services (
NYSE:WST) will be reporting earnings this Thursday morning. Here’s what to expect. West Pharmaceuti...
3 Cash-Producing Stocks We Keep Off Our RadarGenerating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
1 Cash-Heavy Stock to Keep an Eye On and 2 That UnderwhelmCompanies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
3 High-Flying Stocks We Keep Off Our RadarExpensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...
End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces RetirementShares of West Pharmaceutical Services (
NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends to retire. The decline, which wiped out significant market capitalization in a single session, reflects investor anxiety over the
Winners And Losers Of Q4: West Pharmaceutical Services (NYSE:WST) Vs The Rest Of The Drug Development Inputs & Services StocksThe end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development ...
3 Reasons to Sell WST and 1 Stock to Buy InsteadWest Pharmaceutical Services has been treading water for the past six months, recording a small loss of 2.7% while holding steady at $248.28. The stock also ...
1 S&P 500 Stock on Our Watchlist and 2 We Find RiskyThe S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
3 Mid-Cap Stocks with Warning SignsMany investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 Facing HeadwindsWall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
5 Insightful Analyst Questions From West Pharmaceutical Services’s Q4 Earnings CallWest Pharmaceutical Services’ fourth quarter results reflected robust demand for its high-value product components, particularly those tied to biologics and GLP-1 therapies. Management highlighted that non-GLP-1 high-value products also saw improving trends, with CEO Eric Green noting a “strong recovery throughout the year to align to the market demand.” The company benefited from a favorable product mix, as high-value products drove margin expansion despite some headwinds from increased R&D and incentive compensation spending. Operationally, management attributed momentum to capacity investments in its European manufacturing sites and the successful commercialization of new product launches, such as the Synchrony prefillable syringe system, designed specifically for biologics.
